Skip to main content
Caplight Logo









MetrioPharm AG

MetrioPharm AG

Private
ZurichHealthcare & Life Scienceshttps://www.metriopharm.com/

Last Round

VC Round

Oct 1, 2023

Est. Valuation

$163.04M

Total Funding Raised

$59.64M

Company Overview

MetrioPharm AG is a clinical-stage biopharmaceutical company that develops first-in-class, self-regulating immunomodulators for the treatment of inflammatory and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

biopharmaceuticalsmall molecule drugdrug discoveryimmunomodulatoranti-inflammatoryclinical developmentmetabolic modulatoroxidative stressbiotech startupclinical trialsdrug licensingpharma R&Ddrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MetrioPharm AG Comparables

Compare MetrioPharm AG with similar companies based on industry and business-model similarity.

MetrioPharm AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
InflaRx N.V.
74%
Kymera Therapeutics, Inc.
71%
OMEICOS Therapeutics
69%

MetrioPharm AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundOct 1, 2023
GrantOct 12, 2022
VC RoundOct 1, 2022
GrantNov 1, 2021
Series EOct 12, 2021
Series D
Dec 11, 2018

MetrioPharm AG Investors

Notable investors and investment history

MetrioPharm AG investors
InvestorRounds
Duchenne UKGrant
European UnionGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 21, 2026

    Monthly visitors grew 79% MoM, from 616 to 1.1K.

  • Sep 12, 2025

    Professor Dr. Marcus Thelen appointed as Chief Scientific Officer.

MetrioPharm AG Filings

Explore SEC and related filing metadata, where available.

MetrioPharm AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MetrioPharm AG's valuation, stock price, and market status.

Is MetrioPharm AG a public or private company?

MetrioPharm AG is a private company.

What is the current stock price of MetrioPharm AG?

MetrioPharm AG is a private company with no public stock price. No recent secondary market data is available.

How much is MetrioPharm AG worth (valuation)?

MetrioPharm AG's valuation is estimated at $163.0M based on funding round data.

Can I buy MetrioPharm AG stock?

MetrioPharm AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was MetrioPharm AG's last funding round?

MetrioPharm AG's most recent funding round was VC Round on October 1, 2023.

Who are the main investors in MetrioPharm AG?

Key investors in MetrioPharm AG include Duchenne UK, European Union.

Will MetrioPharm AG IPO soon?

No public IPO plans have been announced for MetrioPharm AG.

How can I track MetrioPharm AG secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MetrioPharm AG's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersZurich
Employee Range21
Year Founded2007
Last FundingOct 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?